Immunohematology Market Report 2026

The immunohematology market size has grown steadily in recent years. It will grow from $2.56 billion in 2025 to $2.69 billion in 2026 at a compound annual growth rate (CAGR) of 4.9%. The growth in the historic period can be attributed to increasing prevalence of blood disorders, rising demand for safe blood transfusions, development of blood banks, growth in diagnostic laboratories, advancements in hematology reagents.

The immunohematology market size is expected to see strong growth in the next few years. It will grow to $3.27 billion in 2030 at a compound annual growth rate (CAGR) of 5%. The growth in the forecast period can be attributed to technological advancements in analyzers, adoption of AI in laboratory diagnostics, rise in precision medicine, integration of digital health systems, expansion of blood screening programs. Major trends in the forecast period include advanced blood typing techniques, automation in immunohematology testing, personalized transfusion therapy, point-of-care immune diagnostics, integration of laboratory information systems.

The growing aging population is anticipated to drive the expansion of the immunohematology market in the coming years. An aging population describes a demographic trend marked by a rising proportion of elderly individuals within a society. Immunohematology plays a critical role in meeting age-related transfusion requirements, ensuring the safe use of blood products, and supporting a wide range of medical procedures for older adults. For example, in January 2024, according to the Population Reference Bureau, a US-based nonprofit organization, the number of Americans aged 65 years and older is projected to increase from 58 million in 2022 to 82 million by 2050, representing a 47% rise. During the same period, this age group’s share of the total population is expected to grow from 17% to 23%. Therefore, the expanding aging population is contributing to the growth of the immunohematology market.

Major companies operating in the immunohematology market are focusing on the development of innovative diagnostic solutions, such as soluble recombinant proteins designed to overcome interference caused by the cancer therapy daratumumab. A soluble recombinant protein is produced using recombinant DNA technology and remains properly folded and functional in a soluble form, enabling its effective use in diagnostic and therapeutic applications. For instance, in November 2023, Grifols, S.A., a Spain-based pharmaceutical company, launched the Grifols sCD38 solution. This product is the first soluble recombinant protein developed to address the interference caused by daratumumab during critical blood transfusion compatibility testing. Designed specifically for patients with multiple myeloma, the solution blocks daratumumab from binding to CD38 proteins on red blood cells, enabling accurate pre-transfusion test results. By improving screening, identification, and crossmatching processes, Grifols sCD38 helps streamline transfusion workflows and reduce delays in delivering lifesaving blood products.

In March 2023, Werfen S.A., a Spain-based diagnostic care company, acquired Immucor Inc. for approximately $2 billion. This acquisition was intended to strengthen Werfen’s capabilities in specialized diagnostic testing, particularly in transfusion and immunohematology solutions. Immucor Inc. is a transfusion diagnostics company focused on providing safe, accessible, and reliable blood testing technologies.

Major companies operating in the immunohematology market are Ortho Clinical Diagnostics Inc., Immunocor Inc., Abbott Laboratories, Siemens Healthineers AG, Grifols S.A., Beckman Coulter Inc., Thermo Fisher Scientific Inc., Becton Dickinson and Company, Merck Co. & KGaA, Bio-Rad Laboratories, Sysmex Corporation, Danaher Corporation, Biosystems S.A., Roche Holdings AG, Mindray Medical International Limited, F.Hoffmann La-Roche Ltd., Biotest AG, Cardinal Health Inc., Quotient Limited, DiaSorin S.p.A., Lorne Laboratories Ltd., Biokit S.A., Avox Technologies, Diagnostic Automation/Cortez Diagnostics Inc., Inno-train Diagnostik GmbH, Drucker Diagnostics Inc., Immundia Diagnostics Pvt. Ltd.

North America was the largest region in the immunohematology market in 2025. Asia-Pacific is expected to be the fastest-growing region in the global immunohematology market during the forecast period. The regions covered in the immunohematology market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the immunohematology market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the immunohematology market by increasing the cost of imported analyzers, reagents, and lab equipment, leading to higher operational expenses for diagnostic laboratories and hospitals. Segments such as analyzers and reagents are most impacted, particularly in regions like North America and Europe, which rely on imports from Asia-Pacific manufacturing hubs. While tariffs have created cost pressures, they have also encouraged local production and innovation, driving the development of cost-efficient domestic immunohematology solutions.

The immunohematology market research report is one of a series of new reports that provides immunohematology market statistics, including immunohematology industry global market size, regional shares, competitors with a immunohematology market share, detailed immunohematology market segments, market trends and opportunities, and any further data you may need to thrive in the immunohematology industry. This immunohematology market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Immunohematology is a specialized field of laboratory medicine that focuses on the study of blood groups and the immune system’s response to foreign substances, particularly in the context of blood transfusions. Immunohematological techniques are applied to identify and resolve diagnostic challenges in patients with blood-related disorders, such as autoimmune hemolytic anemia.

The main products in immunohematology include analyzers, systems, and reagents. Analyzers and systems are automated instruments used for blood typing and antibody screening. The technologies employed include biochips, erythrocyte-magnetized technology (EMT), gel cards, microplates, and polymerase chain reaction (PCR), which are used in the diagnosis and management of diseases such as HIV and hepatitis. The key applications include pretransfusion testing, investigation of immune hemolysis, perinatal testing, blood group phenotyping, and leukocyte and platelet serology, and these are utilized by end users such as blood banks, diagnostic and reference laboratories, hospitals, and academic and research institutes.

The immunohematology market includes revenues earned by entities by providing blood banking and transfusion medicine services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.